This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
Viking Therapeutics reported clinical-trial results showing its investigational GLP-1/GIP candidate VK2735 helped participants maintain prior weight loss, including when dosed once monthly. The company’s shares climbed sharply on the news as VK2735 is positioned as a potential rival to Eli Lilly’s Zepbound.
Why It Matters
If confirmed in later-stage testing and regulatory review, a monthly injectable that sustains weight loss could reshape competitive dynamics in the GLP-1/GIP obesity treatment market and affect valuations of companies developing similar therapies.
Key Facts
- Company: Viking Therapeutics
- Drug candidate: VK2735
- Drug class: GLP-1/GIP dual agonist
- Clinical finding: Helped participants maintain weight loss in a trial, including with once-monthly dosing
- Primary competitor mentioned: Eli Lilly's Zepbound (comparative market context)
Viking Therapeutics said its experimental GLP-1/GIP therapy VK2735 enabled trial participants to maintain previously achieved weight loss, including among those who received the drug on a once-monthly schedule. The company presented the results as part of its ongoing development program for the candidate. VK2735 is being developed as a dual agonist of the GLP-1 and GIP pathways, a mechanism shared by several newer obesity and metabolic agents. Viking framed the monthly dosing option as a notable feature of the candidate, because it may offer an alternative to more frequent administration regimens used by some competing products. Market reaction to the announcement was pronounced: Viking’s stock rose significantly after the data were reported. Observers noted the program in part because VK2735 could compete with established and emerging treatments in the same class, including Eli Lilly’s Zepbound. Viking’s findings reflect early-stage clinical data; the company will need to continue with additional trials and regulatory steps before VK2735 could reach the market. The results add to a broader trend of firms advancing long-acting GLP-1/GIP therapies that aim to balance efficacy, dosing frequency, and tolerability profiles.
Keep Reading
My plan to pay off $7,500 in credit-card debt can work for you
Tax-free bond yields are in a sweet spot. Get in before it’s too late.
‘She gave a neighbor $2,000’: Social Security overpaid my mother, 82, by $20,000. What else is hiding in her finances?
‘It doesn’t seem fair’: I’m retired and have plenty of money. Why can’t I qualify for a retail credit card?
Original source: MarketWatch Top Stories